Publication Name	World Journal of Psychiatry
Manuscript ID	105409
Country	Serbia

Received	2025-01-21 02:47
Peer-Review Started	2025-01-21 02:47
To Make the First Decision
Return for Revision	2025-03-24 10:15
Revised	2025-04-04 18:55
Second Decision	2025-05-06 06:58
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-05-13 07:39
Articles in Press	2025-05-13 07:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-05-20 03:03
Publish the Manuscript Online	2025-05-29 09:14

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Minireviews
Article Title	Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride
Manuscript Source	Invited Manuscript
All Author List	Ana V Pejčić
Funding Agency and Grant Number
Corresponding Author	Ana V Pejčić, Assistant Professor, PhD, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com
Key Words	Muscarinic receptors; Schizophrenia; Antipsychotic; Xanomeline; Trospium chloride; Review
Core Tip	Xanomeline/trospium chloride is a potential new treatment option for a wide range of schizophrenia symptoms, offering a relatively favorable tolerability and safety profile. However, additional research is required to better understand its effectiveness and safety in real-world clinical practice, and to define its optimal role in managing this complex psychiatric disorder. As new evidence emerges, it is vital to evaluate it critically.
Publish Date	2025-05-29 09:14
Citation	<p>Pejčić AV. Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride. <i>World J Psychiatry</i> 2025; 15(6): 105409</p>
URL	https://www.wjgnet.com/2220-3206/full/v15/i6/105409.htm
DOI	https://dx.doi.org/10.5498/wjp.v15.i6.105409

Full Article (PDF)	WJP-15-105409-with-cover.pdf
Manuscript File	105409_Auto_Edited_063851.docx
Answering Reviewers	105409-answering-reviewers.pdf
Audio Core Tip	105409-audio.mp3
Conflict-of-Interest Disclosure Form	105409-conflict-of-interest-statement.pdf
Copyright License Agreement	105409-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	105409-non-native-speakers.pdf
Peer-review Report	105409-peer-reviews.pdf
Scientific Misconduct Check	105409-scientific-misconduct-check.png
Scientific Editor Work List	105409-scientific-editor-work-list.pdf
CrossCheck Report	105409-crosscheck-report.pdf